RM-GHA / Growth-hormone-axis signalling
Tesamorelin
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
A growth-hormone-releasing hormone analog. The active appears in an FDA-approved product.
Evidence position
Grade A. An approved comparator exists. Sourced material may differ in salt, formulation, strength, excipients and controls.
What the record does not establish
Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.
Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.
Sources
- 01Egrifta prescribing informationFDA Access Data
- Shows
- Approved label for the finished product
- Does not show
- Describes the approved product only
- 02Randomised clinical trialPubMed
- Shows
- Human interventional data
- Does not show
- Studied the approved presentation
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Tesamorelin
- CID
- 16137828
- Formula
- C221H366N72O67S
- Mass
- 5136
PUBMED / FOUND RECORDS
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews / 2026 Jan 1PMID 41490200 / DOI 10.5435/JAAOSGlobal-D-25-00236
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.The American journal of sports medicine / 2026 JanPMID 41476424 / DOI 10.1177/03635465251357593
- Tesamorelin. / 2012PMID 31644039
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) / 2026 Apr 12PMID 41966639 / DOI 10.1007/s40279-026-02437-0
- Tesamorelin.Nature reviews. Drug discovery / 2011 FebPMID 21283099 / DOI 10.1038/nrd3362
CLINICALTRIALS.GOV / FOUND RECORDS
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVRECRUITING / PHASE2 / Massachusetts General HospitalNCT06554717 / DIRECT intervention MATCH: Tesamorelin
- Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenCOMPLETED / NA / Massachusetts General HospitalNCT00850564 / DIRECT intervention MATCH: Tesamorelin
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentCOMPLETED / PHASE1 / The University of Texas Medical Branch, GalvestonNCT02553603 / DIRECT intervention MATCH: Tesamorelin
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsCOMPLETED / PHASE2 / University of California, San DiegoNCT02572323 / DIRECT intervention MATCH: Tesamorelin
- Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaWITHDRAWN / PHASE2 / National Institute of Nursing Research (NINR)NCT02931474 / DIRECT intervention MATCH: Tesamorelin